Evidence map›Paper›PMID 34135463›Full record

ArticleOncogene2021

Application of machine learning to large in-vitro databases to identify cancer cell characteristics: telomerase reverse transcriptase (TERT) expression.

Jeff Sherman, Grant Verstandig, Yisroel Brumer

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Jeff ShermanZephyr AI, Washington, DC, USA. sherman@redcellpartners.com.ORCID 0000-0003-1377-0357
Grant VerstandigZephyr AI, Washington, DC, USA.
Yisroel BrumerZephyr AI, Washington, DC, USA.ORCID 0000-0002-7046-0198
Zephyr Software (United States) · USRed Hat (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advances in biotechnology and machine learning have created an enhanced environment for unearthing and exploiting previously unrecognized relationships between genomic and epigenetic data with potential therapeutic implications. We applied advanced algorithms to data from the Cancer Dependency Map to uncover increasingly complex relationships. Specifically, we investigate characteristics of tumor cell lines with varying levels of telomerase reverse transcriptase (TERT) expression in liver cancer. The findings indicate that the effect of CRISPR knockout of Histone Deacetylase 1 (HDAC1) and numerous individual respiratory complex I genes is strongly related to the level of TERT expression, with knockout being particularly efficacious at killing or inhibiting growth of tumor cells with low levels of TERT expression for HDAC1 and high levels for Complex I genes. These findings suggest key biomarkers for therapeutic efficacy and yield novel potential pathways for drug development and provide further proof of principle for the potential of artificial intelligence in oncology.

Indexed as

Biomarkers, TumorDatabases, GeneticMachine LearningComputational BiologyGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLiver NeoplasmsMolecular Sequence AnnotationTelomeraseBiomarkers, TumorTelomeraseTERT protein, human

Identifiers

PMID34135463
OpenAlexW3169033193

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.